3320 related articles for article (PubMed ID: 3359400)
1. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
Ceci G; Bella M; Melissari M; Gabrielli M; Bocchi P; Cocconi G
Cancer; 1988 May; 61(10):1988-91. PubMed ID: 3359400
[TBL] [Abstract][Full Text] [Related]
2. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
Erichsen C; Jönsson PE
J Surg Oncol; 1984 Dec; 27(4):268-70. PubMed ID: 6503301
[TBL] [Abstract][Full Text] [Related]
3. [Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
Doering C; Pickartz H; Orfanos CE; Altenähr E
Z Hautkr; 1982 Jul; 57(13):971-80. PubMed ID: 7113323
[TBL] [Abstract][Full Text] [Related]
4. Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Frosch PJ; Czarnetzki BM; Macher E; Grundmann E; Gottschalk I
J Cancer Res Clin Oncol; 1979; 95(3):281-6. PubMed ID: 528568
[TBL] [Abstract][Full Text] [Related]
5. Hepatic veno-occlusive disease due to DTIC.
Asbury RF; Rosenthal SN; Descalzi ME; Ratcliffe RL; Arseneau JC
Cancer; 1980 May; 45(10):2670-4. PubMed ID: 7379000
[TBL] [Abstract][Full Text] [Related]
6. [Budd-Chiari syndrome in DTIC therapy].
Swensson-Beck H; Trettel WH
Hautarzt; 1982 Jan; 33(1):30-1. PubMed ID: 7085277
[TBL] [Abstract][Full Text] [Related]
7. [Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
Leyh F; Winzer M; Weber M; Hypa F
Z Hautkr; 1985 Jun; 60(12):961-72. PubMed ID: 4024678
[TBL] [Abstract][Full Text] [Related]
8. [Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
Runne U; Doepfmer K; Antz H; Groth W; FEAUX DE Lacroix W
Dtsch Med Wochenschr; 1980 Feb; 105(7):230-3. PubMed ID: 6986251
[TBL] [Abstract][Full Text] [Related]
9. Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.
Marsh JC
Hepatology; 1989 May; 9(5):790-2. PubMed ID: 2707742
[No Abstract] [Full Text] [Related]
10. [DTIC: effect on fibrinolysis and thrombocyte function].
Biltz H; Budde U; Fiedler U; Harbrecht U; Kreysel HW
Onkologie; 1986 Oct; 9(5):270-3. PubMed ID: 3543778
[TBL] [Abstract][Full Text] [Related]
11. [Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].
Balda BR; Bassermann R
MMW Munch Med Wochenschr; 1980 May; 122(21):792-4. PubMed ID: 6771598
[TBL] [Abstract][Full Text] [Related]
12. Hepatic vascular lesions associated with dacarbazine treatment.
Greenstone MA; Dowd PM; Mikhailidis DP; Scheuer PJ
Br Med J (Clin Res Ed); 1981 May; 282(6278):1744-5. PubMed ID: 6786601
[TBL] [Abstract][Full Text] [Related]
13. The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
Herishanu Y; Lishner M; Kitay-Cohen Y
Anticancer Drugs; 2002 Feb; 13(2):177-9. PubMed ID: 11901312
[TBL] [Abstract][Full Text] [Related]
14. [Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
Voigt H; Caselitz J; Jänner M
Klin Wochenschr; 1981 Mar; 59(5):229-36. PubMed ID: 7218735
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiological aspects of dacarbazine-induced human liver damage.
Paschke R; Heine M
Hepatogastroenterology; 1985 Dec; 32(6):273-5. PubMed ID: 4093126
[TBL] [Abstract][Full Text] [Related]
16. Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.
Féaux de Lacroix W; Runne U; Hauk H; Doepfmer K; Groth W; Wacker D
Cancer Treat Rep; 1983 Sep; 67(9):779-84. PubMed ID: 6883354
[TBL] [Abstract][Full Text] [Related]
17. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
[TBL] [Abstract][Full Text] [Related]
18. Allergy-induced hepatic toxicity associated with dacarbazine.
McClay E; Lusch CJ; Mastrangelo MJ
Cancer Treat Rep; 1987 Feb; 71(2):219-20. PubMed ID: 3802121
[No Abstract] [Full Text] [Related]
19. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
20. [Photosensitization with DTIC therapy in metastatic malignant melanoma].
Bolling R; Meyer-Hamme S; Schauder S
Hautarzt; 1980 Nov; 31(11):602-5. PubMed ID: 7451142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
